The $40 Billion Race: Bispecific Antibodies Are Redefining Cancer Therapy
(Posted on Thursday, September 18, 2025)
In less than a decade, bispecific antibodies have gone from scientific curiosity to frontline cancer therapeutics. These engineered proteins, capable of binding to two or more targets simultaneously, are reshaping immunotherapy. They are also redrawing the competitive landscape of biopharma itself. With more than 2,000 clinical trials in oncology underway and U.S. cancer drug spending projected to hit $440 billion by 2029, the race is on to harness these molecules.
Five years ago, only a handful of patients had access to bispecific antibody therapies. Today, these drugs are rewriting treatment standards across some of the most challenging cancers. By directly bridging immune cells to tumors or blocking multiple cancer pathways simultaneously, bispecifics have delivered response rates once thought impossible in relapsed myeloma, refractory lymphoma, and even small-cell lung cancer. For patients and physicians, the pace of approval feels less like incremental progress and more like a therapeutic revolution.
What Makes These Antibodies Different
At their core, bispecific antibodies function through dual engagement: one arm binds to a tumor target while the other recruits or redirects immune activity. The most widely used versions are T-cell engagers. The direct tethering transforms resting T cells into potent killers at the tumor site. This is only one mechanism. Other bispecific designs block two growth signaling pathways at once, trap ligands before they can reach receptors, or recruit natural killer cells in addition to T cells.
Multiple myeloma has been a proving ground for these therapies. Drugs like Teclistamab, Talquetamab, and Elranatamab have already earned their place in practice. In July 2025, Linvoseltamab joined the class with results that underscore just how powerful these agents can be. In a trial, patients who had failed four or more lines of treatment—people for whom options had essentially run out—achieved overall response rates above 70%, with nearly half entering complete remission.
The story is equally compelling in lymphomas and leukemia, where the very first bispecific antibody—Blinatumomab, approved back in 2014—set the stage. It has since been joined by Mosunetuzumab, Epcoritamab, and Glofitamab, all of which mobilize T cells against malignant B cells. These drugs have not only extended survival for patients with relapsed disease but have also validated bispecific antibodies as a durable therapeutic class rather than a niche experiment.
Emerging Multispecific Therapies
Cancer has always thrived by exploiting complexity. It’s notorious for evading drugs, resisting monotherapies and rerouting its own biology. The newest wave of multispecific antibodies aims to turn that complexity against the tumor itself. By simultaneously hitting three or more targets, these agents promise not only deeper responses but potentially longer remissions in some of the hardest-to-treat cancers.
If monoclonal antibodies defined the past 25 years, and CAR-T cells the last decade, multispecific antibodies may well shape the next frontier of oncology. These next-generation molecules effectively integrate combination therapy into a single drug, attacking cancer from multiple angles simultaneously. The aim is not incremental improvement, but to stay ahead of the tumor’s notorious ability to adapt and resist.
Read Dr. Haseltine's latest piece with
